Tongqing Zhou

Dr. Tongqing Zhou

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2010 in Science
Verified
Journal Article
Closed access
PDF file
XWXueling Wu
Xueling Wu
ZYZhi-Yong Yang
Zhi-Yong Yang
YLYuxing Li
Yuxing Li
CHCarl-Magnus Hogerkorp
Carl-Magnus Hogerkorp
WSWilliam R. Schief
William R. Schief
JMJohn Mascola
John Mascola
Designer Anti-HIV: Developing a protective HIV vaccine remains a top global health priority. One strategy to identify potential vaccine candidates is to isolate broadly neutralizing antibodies from infected individuals and then attempt to elicit the same antibody response through vaccination (see the Perspective by Burton and Weiss ). Wu et al. (p. 856 , published online 8 July) now report the identification of three broadly neutralizing antibodies, isolated from an HIV-1–infected individual, that exhibited great breadth and potency of neutralization and were specific for the co-receptor CD4-binding site of the glycoprotein 120 (gp120), part of the viral Env spike. Zhou et al. (p. 811 , published online 8 July) analyzed the crystal structure for one of these antibodies, VRC01, in complex with an HIV-1 gp120. VRC01 focuses its binding onto a conformationally invariant domain that is the site of initial CD4 attachment, which allows the antibody to overcome the glycan and conformational masking that diminishes the neutralization potency of most CD4-binding-site antibodies. The epitopes recognized by these antibodies suggest potential immunogens that can inform vaccine design.

22 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
LLLihong Liu
Lihong Liu
PWPengfei Wang
Pengfei Wang
MNManoj S Nair
Manoj S Nair
JYJian Yu
Jian Yu
MRMicah Rapp
Micah Rapp
DHDavid Ho
David Ho

13 August 2010 in Science
Verified
Journal Article
Open access
PDF file
TZTongqing Zhou
Tongqing Zhou
IGIvelin Georgiev
Ivelin Georgiev
XWXueling Wu
Xueling Wu
ZYZhi-Yong Yang
Zhi-Yong Yang
KDKaifan Dai
Kaifan Dai
PKPeter D. Kwong
Peter D. Kwong
Designer Anti-HIV: Developing a protective HIV vaccine remains a top global health priority. One strategy to identify potential vaccine candidates is to isolate broadly neutralizing antibodies from infected individuals and then attempt to elicit the same antibody response through vaccination (see the Perspective by Burton and Weiss ). Wu et al. (p. 856 , published online 8 July) now report the identification of three broadly neutralizing antibodies, isolated from an HIV-1–infected individual, that exhibited great breadth and potency of neutralization and were specific for the co-receptor CD4-binding site of the glycoprotein 120 (gp120), part of the viral Env spike. Zhou et al. (p. 811 , published online 8 July) analyzed the crystal structure for one of these antibodies, VRC01, in complex with an HIV-1 gp120. VRC01 focuses its binding onto a conformationally invariant domain that is the site of initial CD4 attachment, which allows the antibody to overcome the glycan and conformational masking that diminishes the neutralization potency of most CD4-binding-site antibodies. The epitopes recognized by these antibodies suggest potential immunogens that can inform vaccine design.

3 April 2013 in Nature
Verified
Journal Article
Open access
PDF file
LHLiao Huaxin
Liao Huaxin
RLRebecca Lynch
Rebecca Lynch
TZTongqing Zhou
Tongqing Zhou
FGFeng Gao
Feng Gao
SAS. Munir Alam
S. Munir Alam
BHBarton F. Haynes
Barton F. Haynes
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint for effective vaccination. Here we report the isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection. The mature antibody, CH103, neutralized approximately 55% of HIV-1 isolates, and its co-crystal structure with the HIV-1 envelope protein gp120 revealed a new loop-based mechanism of CD4-binding-site recognition. Virus and antibody gene sequencing revealed concomitant virus evolution and antibody maturation. Notably, the unmutated common ancestor of the CH103 lineage avidly bound the transmitted/founder HIV-1 envelope glycoprotein, and evolution of antibody neutralization breadth was preceded by extensive viral diversification in and near the CH103 epitope. These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination.

1 November 2013 in Science
Verified
Journal Article
Closed access
PDF file
JMJason McLellan
Jason McLellan
MCMan Chen
Man Chen
MJM. Gordon Joyce
M. Gordon Joyce
MSMallika Sastry
Mallika Sastry
GSGuillaume B. E. Stewart-Jones
Guillaume B. E. Stewart-Jones
PKPeter D. Kwong
Peter D. Kwong
Designer Vaccine: Respiratory syncytial virus (RSV) is one of the last remaining childhood diseases without an approved vaccine. Using a structure-based approach, McLellan et al. (p. 592 ) designed over 150 fusion glycoprotein variants, assessed their antibody reactivity, determined crystal structures of stabilized variants, and measured their ability to elicit protective responses. This approach yielded an immunogen that elicits higher protective responses than the postfusion form of the fusion glycoprotein, which is one of the current leading RSV vaccine candidates entering clinical trials. Importantly, highly protective responses were elicited in both mice and macaques.

15 October 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
BFBarbara Flynn
Barbara Flynn
KFKathryn E. Foulds
Kathryn E. Foulds
JFJoseph R. Francica
Joseph R. Francica
SBSeyhan Boyoglu-Barnum
Seyhan Boyoglu-Barnum
BGBarney S. Graham
Barney S. Graham
Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Nonhuman primates received 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens. The mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID50) geometric mean titers of 501 in the 10-μg dose group and 3481 in the 100-μg dose group. Vaccination induced type 1 helper T-cell (Th1)–biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100-μg dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group. Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.)